Navigation Links
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
Date:12/7/2009

TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study, TG-0054 exhibited excellent and favorable safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) profile. A maximally tolerated dose (MTD) was established. Good tolerability was observed. PK parameters showed dose proportionality over the dose range studied. PD results showed potent, dose-dependent mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells into peripheral blood circulation.

The preclinical data will be reported on in vitro assays and in vivo studies in mouse models. TG-0054 demonstrated potent and selective antagonistic activities against CXCR4 in vitro. Significant mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells was observed when TG-0054 was used alone or combined with G-CSF in preclinical models.

The preclinical and Phase I results support further clinical investigation. The Phase 2 study entitled "A Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease" will begin to enroll patients in December, 2009.

    ASH 2009 Meeting Presentation:

    Clinical
    Oral presentation: TG-0054, a Novel and Potent Stem Cell Mobilizer,
                       Displays Excellent PK/PD and Safety Profile in Phase 1
                       Trial
    Tuesday, Decem
'/>"/>
SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... 2,clinical trial of picoplatin confirming previously announced interim,results showing a survival ...
... 23 Archus Orthopedics, Inc.,announced today that it ... TFAS-C(TM) system, the newest addition to the company,s ... which degenerative changes in,the facet joints result in ... legs. Traditionally, patients with moderate to,severe spinal stenosis ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4First Human Implant of New Archus Orthopedics Facet Replacement System 2
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
(Date:11/27/2014)... Indian Trail, NC (PRWEB) November 27, 2014 ... for over 12 years in the Charlotte area ... and fraud examination services to businesses of varying ... with local business owners to meet all of ... received QuickBooks certification through the QuickBooks ProAdvisor Program. ...
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
... possibility of risk of cerebral palsy , , WEDNESDAY, Sept. ... of steroids in-utero had no additional growth or neurodevelopmental ... studies found. , However, one of the studies did ... the incidence of cerebral palsy. , "In our ...
... the expanded use of FluMist (influenza virus vaccine live, intranasal) ... now approved for active immunization for the prevention of disease ... to 49 years of age. 1 Only one manufacturer ... influenza vaccine for children under four years of age. , ...
... That Tout Nutrition and Health, WESTLAKE ... of nutrition,in every bite! Dole Packaged Foods, ... Nutritious(TM) Signature Blends-unique combinations of,all-natural frozen fruit ... selections enriched with antioxidants and,immunity health components, ...
... Force, Retaining Cataract Sales ... Force and Lowering Operating Costs, MONROVIA, Calif., ... reported progress in its deployment of a,direct U.S. sales force ... in the retention of key sales,representatives for its cataract products. ...
... A molecular recycling plant permits nerve cells in ... changeable enough to record new experiences, yet permanent ... discovery of this molecular recycling plant, detailed in a ... Neuron, provides new insights into how the basic units ...
... shrink the size of tumors, but some might ... population of cancer stem cells believed to drive ... Atlanta, Georgia at the American Association for Cancer ... in Cancer Therapeutic Development. , Our experiments suggest ...
Cached Medicine News:Health News:Steroids Seem Safe for Babies at Risk of Early Birth 2Health News:Steroids Seem Safe for Babies at Risk of Early Birth 3Health News:Dole Invites Consumers to Show Their Wild Side! 2Health News:STAAR Surgical Reports Operational Progress 2Health News:STAAR Surgical Reports Operational Progress 3Health News:STAAR Surgical Reports Operational Progress 4Health News:New understanding of basic units of memory 2Health News:To evade chemotherapy, some cancer cells mimic stem cells 2
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... Rapidlab 1200's speed and accuracy allow ... in a timely manner - something ... especially patients. In fact, the Rapidlab ... in just one minute. Its maintenance-free, ...
... challenges. One complete solution. , Increased requirements ... Staff turnover. These are just some of ... challenges that can impact the amount of ... , , You can't afford ...
Dornier Holmium Laser for Urological Procedures...
Medicine Products: